Atea Pharmaceuticals, Inc.
NMS: AVIRLive Quote
📈 ZcoreAI Score
Our AI model analyzes Atea Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get AVIR Z-Score →About Atea Pharmaceuticals, Inc.
Healthcare
Biotechnology
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
Atea Pharmaceuticals, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -44.3%, which indicates that capital utilization is currently under pressure.
At a current price of $5.67, AVIR currently trades near the top of its 52-week range (80%) (Range: $2.46 - $6.45).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$451.74M
Trailing P/E
--
Forward P/E
-4.09
Beta (5Y)
0.16
52W High
$6.45
52W Low
$2.46
Avg Volume
557K
Day High
Day Low